Patient Care & Treatment

orkambi for cystic fibrosis
Patient Care & Treatment Respiratory

FDA Approves ORKAMBI®, First Medicine to Treat the Underlying Cause of CF for Children Ages 2-5 Years with Most Common Form of the Disease

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF […]